SCHEMBL3448113

SCHEMBL3448113

CNc1ncc(-c2cnc(Nc3cc(OC)cc(OC)c3)nc2-n2ccc(C(F)(F)F)n2)cc1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 6/20 0.40
TYRO3 Q06418 1/20 0.39
MERTK Q12866 1/20 0.39
MAPK3 P27361 1/20 0.39
PTK2 Q05397 2/20 0.38
CNR2 P34972 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CDK2 P24941 2/20 0.36
GSK3B P49841 2/20 0.36
STK16 O75716 1/20 0.36
CLK1 P49759 1/20 0.36
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
CDK4 P11802 1/20 0.36
HDAC3 O15379 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449402 0.94 TYRO3 (0.40) SYKTYRO3MERTKMAPK3PTK2
SCHEMBL3375491 0.91 SYK (0.41) SYKTYRO3MERTKMAPK3CNR2
SCHEMBL3451579 0.89 SYK (0.40) SYKTYRO3MERTKMAPK3CNR2
SCHEMBL3376598 0.88 SYK (0.39) SYKTYRO3MERTKMAPK3CNR2
SCHEMBL3448222 0.88 AXL (0.36) SYKTYRO3MERTKMAPK3CNR2
SCHEMBL3448316 0.87 SYK (0.40) SYKTYRO3MERTKMAPK3CNR2
SCHEMBL3376264 0.87 SYK (0.46) SYK
SCHEMBL3448415 0.87 SYK (0.39) SYKTYRO3MERTKMAPK3CNR2
SCHEMBL3451240 0.87 PTK2 (0.41) TYRO3MERTKMAPK3PTK2CNR2
SCHEMBL3376690 0.86 TYRO3 (0.40) SYKTYRO3MERTKMAPK3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD SYK 804/4885TYRO3 2798/4885MERTK 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.